Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (64)

« Back to Publications

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.

Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).

Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

Rift Valley fever seroprevalence and risk factors among human populations in Uganda's cattle corridor: a cross-sectional study.

Anywaine Z. et al, (2025), BMJ Public Health, 3

Adenoviral vaccines—Infectious disease

Bliss CM. et al, (2025), 573 - 642

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.

Satti I. et al, (2024), Lancet Infect Dis, 24, 909 - 921

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

Flaxman A. et al, (2024), PLoS Pathog, 20

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.

Peralta Alvarez MP. et al, (2024), Front Immunol, 15

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Hamaluba M. et al, (2023), Wellcome open research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

Hamaluba M. et al, (2023), Wellcome Open Research, 8, 182 - 182

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.

Hamaluba M. et al, (2023), Wellcome Open Res, 8

Characterisation of the protective immune response to Rift Valley fever virus after natural exposure or vaccination with ChAdOx1 RVF

Wright D., (2022)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.

Berg A. et al, (2021), Vaccines (Basel), 9

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Load More

1
2
3
4
5